[go: up one dir, main page]

CY1124069T1 - Ανοσιακα κυτταρα ελαττωματικα για suv39η1 - Google Patents

Ανοσιακα κυτταρα ελαττωματικα για suv39η1

Info

Publication number
CY1124069T1
CY1124069T1 CY20211100309T CY211100309T CY1124069T1 CY 1124069 T1 CY1124069 T1 CY 1124069T1 CY 20211100309 T CY20211100309 T CY 20211100309T CY 211100309 T CY211100309 T CY 211100309T CY 1124069 T1 CY1124069 T1 CY 1124069T1
Authority
CY
Cyprus
Prior art keywords
immune cell
suv39h1
genetically engineered
immune cells
cells defective
Prior art date
Application number
CY20211100309T
Other languages
English (en)
Inventor
Sebastian Amigorena
Eliane Piaggio
Christel GOUDOT
Luigia PACE
Geneviève Almouzni
Original Assignee
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie filed Critical Institut Curie
Publication of CY1124069T1 publication Critical patent/CY1124069T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα κατασκευασμένο μέσω γενετικής μηχανικής ανοσιακό κύτταρο ελαττωματικό για Suv39h1. Προτιμώμενα, το εν λόγω κατασκευασμένο μέσω γενετικής μηχανικής ανοσιακό κύτταρο περιλαμβάνει περαιτέρω έναν γενετικώς κατασκευασμένο μέσω μηχανικής υποδοχέα αντιγόνων που δεσμεύει συγκεκριμένα ένα αντιγόνο στόχο. Η παρούσα εφεύρεση σχετίζεται επίσης με μια μέθοδο για λήψη ενός γενετικώς κατασκευασμένου μέσω γενετικής μηχανικής ανοσιακού κυττάρου περιλαμβάνοντας ένα βήμα συνιστάμενο από αναστολή της έκφρασης και/ή δραστηριότητας του Suv39h1 στο ανοσιακό κύτταρο• και περαιτέρω περιλαμβάνοντας προαιρετικώς ένα βήμα συνιστάμενο από εισαγωγή στο εν λόγω ανοσιακό κύτταρο έναν γενετικώς κατασκευασμένου μέσω μηχανικής υποδοχέα αντιγόνων που δεσμεύεται συγκεκριμένα σε ένα αντιγόνο στόχο. Η εφεύρεση εμπερικλείει επίσης το εν λόγω κατασκευασμένο μέσω γενετικής μηχανικής ανοσιακό κύτταρο για τη χρήση αυτών σε υιοθετική θεραπεία, σημειωτέον για την αγωγή του καρκίνου.
CY20211100309T 2017-06-20 2021-04-12 Ανοσιακα κυτταρα ελαττωματικα για suv39η1 CY1124069T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305757 2017-06-20
PCT/EP2018/066387 WO2018234370A1 (en) 2017-06-20 2018-06-20 Immune cells defective for suv39h1

Publications (1)

Publication Number Publication Date
CY1124069T1 true CY1124069T1 (el) 2022-05-27

Family

ID=59295130

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100309T CY1124069T1 (el) 2017-06-20 2021-04-12 Ανοσιακα κυτταρα ελαττωματικα για suv39η1

Country Status (23)

Country Link
US (5) US10576103B2 (el)
EP (2) EP3538645B1 (el)
JP (2) JP7388798B2 (el)
KR (1) KR20200027512A (el)
CN (3) CN110997902B (el)
AU (1) AU2018287042A1 (el)
BR (2) BR122020025496B8 (el)
CA (1) CA3067446A1 (el)
CY (1) CY1124069T1 (el)
DK (1) DK3538645T3 (el)
ES (1) ES2871400T3 (el)
HR (1) HRP20210567T1 (el)
HU (1) HUE053760T2 (el)
IL (1) IL271618B2 (el)
LT (1) LT3538645T (el)
MX (2) MX2019015841A (el)
PL (1) PL3538645T3 (el)
PT (1) PT3538645T (el)
RS (1) RS61691B1 (el)
SG (1) SG11201912455VA (el)
SI (1) SI3538645T1 (el)
SM (1) SMT202100206T1 (el)
WO (1) WO2018234370A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3538645T3 (pl) 2017-06-20 2021-11-08 Institut Curie Komórki odpornościowe z defektem suv39h1
WO2021013950A1 (en) * 2019-07-23 2021-01-28 Mnemo Therapeutics Immune cells defective for suv39h1
CN116406421A (zh) * 2021-07-13 2023-07-07 苏州沙砾生物科技有限公司 一种免疫细胞的培养方法及其用途
EP4456910A1 (en) * 2021-12-28 2024-11-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
CA3247927A1 (en) * 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
CN120077132A (zh) 2022-01-21 2025-05-30 姆内莫治疗公司 Rna对suv39h1表达的调控
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
EP4598565A1 (en) 2022-10-07 2025-08-13 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
CN118995620A (zh) * 2023-05-16 2024-11-22 清华大学 一种嵌合抗原受体、重组免疫细胞及用途
AU2024284143A1 (en) * 2023-06-07 2025-10-23 Fbd Biologics Limited Engineered il-7 variants and methods of use thereof
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566A (en) 1849-07-03 Manufacture of bags and sacks
US131A (en) 1837-02-24 Machine foe cutting eur fedm skins
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
WO2009126537A1 (en) * 2008-04-07 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an hmt inhibitor
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
US8603477B2 (en) 2008-10-31 2013-12-10 Abbvie Biotherapeutics Inc. Use of anti-CS1 antibodies for treatment of rare lymphomas
WO2011009173A1 (en) 2009-07-23 2011-01-27 Mater Medical Research Institute Cancer immunotherapy
NO2510096T3 (el) 2009-12-10 2015-03-21
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
EA201391449A1 (ru) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013050405A1 (en) * 2011-10-03 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of th2 mediated diseases
EP2763670B1 (en) * 2011-10-03 2018-12-05 Universite Libre De Bruxelles Reactivation of hiv-1 gene expression to treat persistent hiv infection
ES2687954T3 (es) 2011-11-11 2018-10-30 Fred Hutchinson Cancer Research Center Inmunoterapia de linfocitos T dirigidos a ciclina A1 contra el cáncer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2018130123A (ru) 2012-05-03 2018-11-07 Фред Хатчинсон Кансэр Рисёч Сентер Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
CN104853766A (zh) 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
US20140161785A1 (en) * 2012-12-10 2014-06-12 Feiyan Liu Verticillin A Inhibition of Histone Methyltransferases
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014097442A1 (ja) 2012-12-20 2014-06-26 三菱電機株式会社 車載装置及びプログラム
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
PL3538645T3 (pl) * 2017-06-20 2021-11-08 Institut Curie Komórki odpornościowe z defektem suv39h1

Also Published As

Publication number Publication date
CN114350613B (zh) 2024-12-31
US12371471B2 (en) 2025-07-29
SG11201912455VA (en) 2020-01-30
IL271618A (en) 2020-02-27
HUE053760T2 (hu) 2021-07-28
CN110997902B (zh) 2021-11-30
US11285176B2 (en) 2022-03-29
PT3538645T (pt) 2021-04-15
RS61691B1 (sr) 2021-05-31
IL271618B2 (en) 2024-06-01
RU2020101755A3 (el) 2021-08-16
LT3538645T (lt) 2021-04-26
EP3828264A1 (en) 2021-06-02
JP2024023299A (ja) 2024-02-21
US20220040235A1 (en) 2022-02-10
US20230201264A1 (en) 2023-06-29
DK3538645T3 (da) 2021-04-19
SMT202100206T1 (it) 2021-07-12
SI3538645T1 (sl) 2021-08-31
US20190365807A1 (en) 2019-12-05
PL3538645T3 (pl) 2021-11-08
US11622978B2 (en) 2023-04-11
KR20200027512A (ko) 2020-03-12
CN110997902A (zh) 2020-04-10
US10576103B2 (en) 2020-03-03
US20200171090A1 (en) 2020-06-04
US20250011389A1 (en) 2025-01-09
IL271618B1 (en) 2024-02-01
JP7706523B2 (ja) 2025-07-11
HRP20210567T1 (hr) 2021-09-03
CN114058590B (zh) 2024-08-06
BR112019027133B8 (pt) 2022-08-09
ES2871400T3 (es) 2021-10-28
CN114350613A (zh) 2022-04-15
BR112019027133A2 (pt) 2020-07-07
JP7388798B2 (ja) 2023-11-29
AU2018287042A1 (en) 2020-02-06
EP3538645B1 (en) 2021-01-20
BR122020025496B8 (pt) 2023-10-24
CA3067446A1 (en) 2018-12-27
ES2871400T8 (es) 2022-03-31
MX2019015841A (es) 2020-08-03
JP2020523995A (ja) 2020-08-13
RU2020101755A (ru) 2021-07-20
WO2018234370A1 (en) 2018-12-27
BR122020025496B1 (pt) 2023-09-26
EP3538645A1 (en) 2019-09-18
MX2023006039A (es) 2023-06-02
CN114058590A (zh) 2022-02-18
BR112019027133B1 (pt) 2022-07-19

Similar Documents

Publication Publication Date Title
CY1124069T1 (el) Ανοσιακα κυτταρα ελαττωματικα για suv39η1
CY1123868T1 (el) Συνδυαστικη ανοσοθεραπεια ογκου
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
CY1123972T1 (el) Θεραπεια συνδυασμου για καρκινο
CY1124437T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
CY1124558T1 (el) Προβλεψη επιτοπων τ κυτταρων χρησιμων για εμβολιασμο
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
CY1124628T1 (el) Συζευγματα αντισωματος-φαρμακου βασει εριβουλινης και μεθοδοι χρησεως
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123858T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1123556T1 (el) Αντισωμα που δεσμευει τις erbb-2 και erbb-3
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
CY1122472T1 (el) Συζευγμα-αντισωματος-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
CY1121783T1 (el) Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
BR112019009925A2 (pt) método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
MX2017013777A (es) Metodo para el tratamiento de cancer.